GlassScriptPhysician profile
Ben W Doke
NPI 1215948450
$3,740.30
in general payments reported to CMS, 2019-2025
35 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $413 · 2021: $503 · 2022: $815 · 2023: $436 · 2024: $367 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.99 | 2019-2024 | |
| Axonics, INC. | $487.70 | 2021-2023 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $374.16 | 2019-2023 | |
| Amgen INC. | $279.98 | 2019-2025 | Evenity, Prolia, Prolia |
| Daiichi Sankyo INC. | $206.99 | 2021-2024 | Injectafer |
| Astellas Pharma US INC | $183.27 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $178.48 | 2019-2022 | |
| Radius Health, INC. | $152.38 | 2023-2025 | Tymlos |
| Biogen, INC. | $142.04 | 2025 | Zurzuvae |
| Organon LLC | $133.74 | 2022-2025 | Jada System, Nexplanon |
| Intuitive Surgical, INC. | $102.58 | 2019-2022 | |
| Spineart Sa | $102.55 | 2024 | |
| Allergan, INC. | $80.69 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $77.55 | 2019-2020 | |
| Hologic Sales and Service, LLC | $73.25 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $62.85 | 2019 | |
| Vivus LLC | $55.30 | 2020-2022 | |
| Coopersurgical, INC. | $45.91 | 2020 | |
| Avion Pharmaceuticals | $44.92 | 2019-2020 | |
| Shield Therapeutics INC | $43.40 | 2023-2025 | |
| Lilly USA, LLC | $42.56 | 2019-2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $41.29 | 2020-2021 | |
| Boston Scientific Corporation | $34.91 | 2023-2025 | Spyglass Discover, Spyglass |
| Pacira Pharmaceuticals Incorporated | $34.05 | 2025 | Exparel |
| Therapeuticsmd, INC. | $31.57 | 2022 | |
| Ethicon US, LLC | $25.86 | 2022 | |
| Vertical Pharmaceuticals, LLC | $24.94 | 2019 | |
| Sumitomo Pharma America, INC. | $22.77 | 2025 | Myfembree |
| Ortho-Clinical Diagnostics, INC. | $21.49 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.36 | 2021 | |
| Pfizer INC. | $13.49 | 2024 | |
| Genentech USA, INC. | $12.96 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.46 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Doke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.